基因多态性与高血压及钙拮抗剂疗效的相关性
摘要
高血压是广泛危害人类健康的慢性病之一,随着基因分析技术的发展,发现基因多态性与高血压的发病密切相关,对高血压的预防具有早期警示作用;钙离子拮抗剂具有稳定的降压效果,但疗效具有明显的个体差异,可能与遗传变异相关。本文在药物基因组学研究的基础上,对基因多态性与高血压及钙拮抗剂疗效的相关性作一综述,从而为高血压的个体化治疗提供依据。
引文
[1]金来润,范静宜,王仲男,等.中国大陆地区吲达帕胺联合氨氯地平治疗高血压合并冠心病的Meta分析[J].右江民族医学院学报,2018,40(4):367-370,376.
[2]Thoenes M,Neuberger HR,Volpe M,et al.Antihypertensive drug therapy and blood pressure control in men and women:an international perspective[J].Journal of Human Hypertension,2010,24(5):336-344.
[3]Li Z,Chen P,Zhou T,et al.Association between CYP3A5genotypes with hypertension in Chinese Han population:A case-control study[J].Clinical and Experimental Hypertension,2017,39(3):235-240.
[4]Ferraresso M,Turolo S,Ghio L,et al.Association between CYP3A5polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors[J].Clinical and Experimental Hypertension,2011,33(6):359-365.
[5]Xiang Q,Li C,Zhao X.The influence of CYP3A5*3and BCRPC421Agenetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers[J].Journal of Clinical Pharmacy and Therapeutics,2017,42(3):345-349.
[6]Huang Y,Wen G,Lu Y,et al.CYP3A4*1Gand CYP3-A5*3genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation[J].Int J Clin Pharmacol Ther,2017,55(2):109-118.
[7]Bhatnagar V,Garcia EP,O’Connor DT,et al.CYP3A4and CYP3A5polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease[J].American Journal of Nephrology,2010,31(2):95-103.
[8]Hu Z,Liu F,Li M,et al.Associations of Variants in the CACNA1A and CACNA1C Genes With Longitudinal Blood Pressure Changes and Hypertension Incidence:The GenSalt Study[J].American Journal of Hypertension,2016,29(11):1301-1306.
[9]Kamide K,Yang J,Matayoshi T,et al.Genetic polymorphisms of L-type calcium channel alpha1Cand alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers[J].Circulation Journal,2009,73(4):732-740.
[10]Sun Q,Li QX,Song XF,et al.Impact of CACNA1Cpolymorphisms on antihypertensive efficacy of calcium channel blocker[J].Zhonghua Xin Xue Guan Bing Za Zhi,2012,40(1):3-7.
[11]Simonyte S,Kuciene R,Dulskiene V,et al.Association between ATP2B1and CACNB2 polymorphisms and high blood pressure in a population of Lithuanian children and adolescents:a cross-sectional study[J].BMJ Open,2018,8(7):e019902.
[12]Hong GL,Chen XZ,Liu Y,et al.Genetic variations in MOV10and CACNB2are associated with hypertension in a Chinese Han population[J].Genetics and Molecular Research,2013,12(4):6220-6227.
[13]Lin Y,Lai X,Chen B,et al.Genetic variations in CYP17A1,CACNB2 and PLEKHA7 are associated with blood pressure and/or hypertension in She ethnic minority of China[J].Atherosclerosis,2011,219(2):709-714.
[14]李清贤,孙倩,宋喜发,等.CACNB2基因多态性与钙离子通道阻滞剂降压疗效的相关性研究[J].医学研究杂志,2012,41(3):46-49.
[15]El Din Hemimi NS,Mansour AA,Abdelsalam MM.Prediction of the Risk for Essential Hypertension among Carriers of C825TGenetic Polymorphism of G Proteinβ3(GNB3)Gene[J].Biomark Insights,2016,11:69-75.
[16]Sousa AC,Reis RPD,Pereira A,et al.The genetic variant C825Tof the beta 3subunit of G protein is associated with hypertension in a Portuguese population[J].Rev Port Cardiol,2018,37(6):499-507.
[17]Rong SL,Zheng JZ,Wang XL,et al.Association of Gproteinβ3subunit C825Tpolymorphism with essential hypertension:evidence from 63729subjects[J].Journal of Human Hypertension,2017,31(8):511-514.
[18]应剑,冯雁,黄爱群,等.G蛋白β3亚基基因(GNB3)C825T多态性影响硝苯地平控释片15d降压幅度[J].中国药理学通报,2003(9):1013-1016.
[19]Zhang ZL,Li HL,Wen ZP,et al.Influence of G-proteinβ-Polypeptide 3C825TPolymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients[J].Chinese Medical Journal,2016,129(1):8-14.
[20]Yue Q,Xiong B,Chen L,et al.MDR1C3435Tpolymorphism and childhood acute lymphoblastic leukemia susceptibility:an updated meta-analysis[J].Biomed Pharmacother,2015,69:76-81.
[21]Manna I,Gambardella A,Labate A,et al.Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1C3435Tand response to antiepileptic drug treatment in temporal lobe epilepsy[J].Seizure,2015,24:124-126.
[22]Lacchini R,Figueiredo VN,Demacq C,et al.MDR-1C3435Tpolymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release[J].JRAAS,2014,15(2):170-176.
[23]Zhang XW,Yang JL,Liang W,et al.Genetic association study of ABCB1gene polymorphisms with hypertension in Han Chinese population[J].European Review for Medical and Pharmacological Sciences,2016,20(17):3661-3671.
[24]Sychev DA,Shih NV,Kalle EG,et al.Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension[J].Biomed Khim,2017,63(5):432-439.
[25]Guo C,Pei QI,Tan H,et al.Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients[J].Biomedical Reports,2015,3(2):195-200.
[26]Georgianos PI,Agarwal R.Endothelin A receptor antagonists in diabetic kidney disease[J].Current Opinion in Nephrology and Hypertension,2017,26(5):338-344.
[27]董艳丽.原发性高血压患者血清hs-CRP、ADPN、NO和ET-1水平的变化研究[J].现代诊断与治疗,2018,29(5):780-782.
[28]Rankinen T,Church T,Rice T,et al.Effect of endothelin1genotype on blood pressure is dependent on physical activity or fitness levels[J].Hypertension,2007,50(6):1120-1125.
[29]王镇,张勇,吴恳,等.ET-1基因多态性与海南黎族人原发性高血压的相关性[J].中国老年学杂志,2014,34(17):4790-4792.
[30]方正旭.ET-1、eNOS基因多态性与江西汉族人群原发性高血压及硝苯地平降压疗效的相关性研究[D].南昌:南昌大学,2016.
[2]Thoenes M,Neuberger HR,Volpe M,et al.Antihypertensive drug therapy and blood pressure control in men and women:an international perspective[J].Journal of Human Hypertension,2010,24(5):336-344.
[3]Li Z,Chen P,Zhou T,et al.Association between CYP3A5genotypes with hypertension in Chinese Han population:A case-control study[J].Clinical and Experimental Hypertension,2017,39(3):235-240.
[4]Ferraresso M,Turolo S,Ghio L,et al.Association between CYP3A5polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors[J].Clinical and Experimental Hypertension,2011,33(6):359-365.
[5]Xiang Q,Li C,Zhao X.The influence of CYP3A5*3and BCRPC421Agenetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers[J].Journal of Clinical Pharmacy and Therapeutics,2017,42(3):345-349.
[6]Huang Y,Wen G,Lu Y,et al.CYP3A4*1Gand CYP3-A5*3genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation[J].Int J Clin Pharmacol Ther,2017,55(2):109-118.
[7]Bhatnagar V,Garcia EP,O’Connor DT,et al.CYP3A4and CYP3A5polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease[J].American Journal of Nephrology,2010,31(2):95-103.
[8]Hu Z,Liu F,Li M,et al.Associations of Variants in the CACNA1A and CACNA1C Genes With Longitudinal Blood Pressure Changes and Hypertension Incidence:The GenSalt Study[J].American Journal of Hypertension,2016,29(11):1301-1306.
[9]Kamide K,Yang J,Matayoshi T,et al.Genetic polymorphisms of L-type calcium channel alpha1Cand alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers[J].Circulation Journal,2009,73(4):732-740.
[10]Sun Q,Li QX,Song XF,et al.Impact of CACNA1Cpolymorphisms on antihypertensive efficacy of calcium channel blocker[J].Zhonghua Xin Xue Guan Bing Za Zhi,2012,40(1):3-7.
[11]Simonyte S,Kuciene R,Dulskiene V,et al.Association between ATP2B1and CACNB2 polymorphisms and high blood pressure in a population of Lithuanian children and adolescents:a cross-sectional study[J].BMJ Open,2018,8(7):e019902.
[12]Hong GL,Chen XZ,Liu Y,et al.Genetic variations in MOV10and CACNB2are associated with hypertension in a Chinese Han population[J].Genetics and Molecular Research,2013,12(4):6220-6227.
[13]Lin Y,Lai X,Chen B,et al.Genetic variations in CYP17A1,CACNB2 and PLEKHA7 are associated with blood pressure and/or hypertension in She ethnic minority of China[J].Atherosclerosis,2011,219(2):709-714.
[14]李清贤,孙倩,宋喜发,等.CACNB2基因多态性与钙离子通道阻滞剂降压疗效的相关性研究[J].医学研究杂志,2012,41(3):46-49.
[15]El Din Hemimi NS,Mansour AA,Abdelsalam MM.Prediction of the Risk for Essential Hypertension among Carriers of C825TGenetic Polymorphism of G Proteinβ3(GNB3)Gene[J].Biomark Insights,2016,11:69-75.
[16]Sousa AC,Reis RPD,Pereira A,et al.The genetic variant C825Tof the beta 3subunit of G protein is associated with hypertension in a Portuguese population[J].Rev Port Cardiol,2018,37(6):499-507.
[17]Rong SL,Zheng JZ,Wang XL,et al.Association of Gproteinβ3subunit C825Tpolymorphism with essential hypertension:evidence from 63729subjects[J].Journal of Human Hypertension,2017,31(8):511-514.
[18]应剑,冯雁,黄爱群,等.G蛋白β3亚基基因(GNB3)C825T多态性影响硝苯地平控释片15d降压幅度[J].中国药理学通报,2003(9):1013-1016.
[19]Zhang ZL,Li HL,Wen ZP,et al.Influence of G-proteinβ-Polypeptide 3C825TPolymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients[J].Chinese Medical Journal,2016,129(1):8-14.
[20]Yue Q,Xiong B,Chen L,et al.MDR1C3435Tpolymorphism and childhood acute lymphoblastic leukemia susceptibility:an updated meta-analysis[J].Biomed Pharmacother,2015,69:76-81.
[21]Manna I,Gambardella A,Labate A,et al.Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1C3435Tand response to antiepileptic drug treatment in temporal lobe epilepsy[J].Seizure,2015,24:124-126.
[22]Lacchini R,Figueiredo VN,Demacq C,et al.MDR-1C3435Tpolymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release[J].JRAAS,2014,15(2):170-176.
[23]Zhang XW,Yang JL,Liang W,et al.Genetic association study of ABCB1gene polymorphisms with hypertension in Han Chinese population[J].European Review for Medical and Pharmacological Sciences,2016,20(17):3661-3671.
[24]Sychev DA,Shih NV,Kalle EG,et al.Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension[J].Biomed Khim,2017,63(5):432-439.
[25]Guo C,Pei QI,Tan H,et al.Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients[J].Biomedical Reports,2015,3(2):195-200.
[26]Georgianos PI,Agarwal R.Endothelin A receptor antagonists in diabetic kidney disease[J].Current Opinion in Nephrology and Hypertension,2017,26(5):338-344.
[27]董艳丽.原发性高血压患者血清hs-CRP、ADPN、NO和ET-1水平的变化研究[J].现代诊断与治疗,2018,29(5):780-782.
[28]Rankinen T,Church T,Rice T,et al.Effect of endothelin1genotype on blood pressure is dependent on physical activity or fitness levels[J].Hypertension,2007,50(6):1120-1125.
[29]王镇,张勇,吴恳,等.ET-1基因多态性与海南黎族人原发性高血压的相关性[J].中国老年学杂志,2014,34(17):4790-4792.
[30]方正旭.ET-1、eNOS基因多态性与江西汉族人群原发性高血压及硝苯地平降压疗效的相关性研究[D].南昌:南昌大学,2016.